POLYIRAN Liver Study

It is evident that the presence of nonalcoholic steatohepatitis (NASH) leads to an increased rate of atherosclerotic events. It is also suspected that some of the ingredients of PolyPill might have beneficial effects on NASH. In the light of these evidence, a pilot study has been designed similar to the PolyIran study but with special emphasis on some liver-related variables. The study includes a random selection of 1500 subjects from Golestan Cohort Study subjects residing in Gonbad city in North Iran. Subjects are randomized into two groups receiving a single-dose fixed-combination pill (PolyPill) or not. In addition to the measurements made in the PolyIran study, subjects in the PolyIran-Liver study also undergo abdominal ultrasonography, liver stiffness measurement, and color Doppler ultrasonography of carotid arteries. Subjects will be followed for 5 years and the same measurements will be repeated at the end of this period. The protective effect of PolyPill on atherosclerotic events and ultrasonography and liver stiffness will be evaluated as well as the differential effects based on baseline liver health state.